May 2019 Issue of CEO Today to Feature Interview with Co-Diagnostics Inc CEO

New York, New York, UNITED STATES

New York City, May 07, 2019 (GLOBE NEWSWIRE) -- May 2019 Issue of CEO Today to Feature Interview with Co-Diagnostics Inc CEO

The May 2019 issue of CEO Today Magazine, dedicated to providing CEOs and C-level executives with the latest corporate developments, business news, and technological innovations, will include an Executive Insight interview with Dwight Egan, CEO of Co-Diagnostics, Inc.

The feature covering Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, and client of BDA International, comprises a variety of subjects. These include a layman’s explanation of how polymerase chain reaction (PCR) works, the PCR technologies used by the Company and their applications (liquid biopsy, AgBio uses and next generation sequencing, in addition to infectious disease diagnostics) and how owning their own platform lowers overheads and creates cost savings passed on to the end users.

In discussing the size of the market and potential reach of their products, Mr. Egan remarks:

The molecular diagnostics market as a whole has seen incredible growth over the last several years, and has been projected to exceed $12.5 billion over the next 5 years. With that growth has come interest from enterprise and non-profit participants alike, which interest has in turn spurred developments in many different applications of PCR testing technology. This market includes infectious disease detection, cancer detection, genetic sequencing and others—all areas where we believe our technology brings further value and innovation.

Release of the interview follows recent news by the company that a provisional patent has been filed related to its single-step next generation sequencing (NGS) library preparation methods and composition, claiming an exclusive privilege and/or right to practice the invention, which also embodies the use of the company’s patented CoPrimer™ technology in the process.

A direct link to the interview may be found here:

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles may also in some circumstances hold some of shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.


Co-Diagnostics is a client of BDA International. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at Investing in securities is speculative and carries risk.

Investor Relations Contact:                                                                               
BDA International        

Source: BDA International